⚙
AI-generated summary
by gemini-2.5-flash-lite, 2026-06-09
ⓘ
This study describes and evaluates transrectal ultrasound-guided high-intensity focused ultrasound (TR-USgHIFU) for rectosigmoid endometriosis, finding it feasible and safe with promising clinical symptom improvement, though morphological efficacy requires further demonstration.
⚙
AI-generated deep summary
by qwen3.7-flash, 2026-08-23
· read from full text
ⓘ
The provided text does not contain the actual content of a research paper but rather displays a security challenge page from a website protected by Anubis. This page explains that the site uses a Proof-of-Work scheme to prevent automated scraping by AI companies and requires modern JavaScript features to proceed. Consequently, no scientific data, methods, or findings regarding high-intensity focused ultrasound (HIFU) for endometriosis are available in the input. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Abstract
OBJECTIVES: In this thesis we describe a new technique for the management of rectosigmoid endometriosis by transrectal ultrasound-guided high intensity focused ultrasound ultrasound (TR-USgHIFU). We also review several limiting factors of this technique before assessing several modifications to improve the feasibility and the efficacy of the procedure. METHODS: We first conducted a phase I clinical trial to test the feasibility of TR-USgHIFU treatment using the FocalOne® device. We then carried out a study on anatomical specimens to assess the limiting factors of the FocaleOne® probe and to test another HIFU probe, which has smaller transducer and which is mounted on a flexible endoscope. We also performed an observational clinical study to measure the acoustic attenuation of rectosigmoid endometriosis lesions and that of normal bowel. Finally, we have developed a murine model of subcutaneous endometriosis to assess the pathophysiological effects of HIFU on endometriosis. RESULTS: We included 23 patients in the phase I clinical trial between June 2015 and October 2019. Treatment was carried out in 20 of these patients (87% feasibility). No serious adverse events have been reported. We did not find a significant morphological effect at 6 months, but we report a significant improvement on digestive and gynecological symptoms as well as on patients’ quality of life. Studies on anatomical specimens and on MRI pictures demonstrated the role of the sacrum and the recto-sigmoid hinge in the mechanical limitations of the FocalOne® probe. The use of a smaller probe with a shorter focal could be interesting in order to increase the feasibility of the treatment. Our study on 13 patients treated surgically for rectum or sigmoid endometriosis nodule, showed that attenuation of digestive endometriosis at 3 MHz is 50.2 Np / m. This value was significantly higher than attenuation of the normal bowel (32.8; p <0.001). We finally showed that the heterologous subcutaneous murine model "BALB / c-nude # Ishikawa" was reliable and efficient to study the effects of HIFU on digestive endometriosis, as the acoustic attenuation of its nodules are remarkably close to that of endometriosis lesions. Thanks to this model, we reported that HIFU lesions are associated with a higher rate of ischemic and coagulation necrosis. CONCLUSIONS: Treatment with TR-USgHIFU in rectosigmoid endometriosis is feasible and safe. Its morphological efficacy remains to be demonstrated, but its significant clinical efficacy is promising. It could become be a minimally invasive alternative to replace surgical treatment in this indication, especially for rectal lesions
Full text
1,068 characters
· extracted from
oa-html
· click to expand
Making sure you're not a bot!
Loading...
You are seeing this because the administrator of this website has set up Anubis to protect the server against the scourge of AI companies aggressively scraping websites. This can and does cause downtime for the websites, which makes their resources inaccessible for everyone.
Anubis is a compromise. Anubis uses a Proof-of-Work scheme in the vein of Hashcash, a proposed proof-of-work scheme for reducing email spam. The idea is that at individual scales the additional load is ignorable, but at mass scraper levels it adds up and makes scraping much more expensive.
Ultimately, this is a placeholder solution so that more time can be spent on fingerprinting and identifying headless browsers (EG: via how they do font rendering) so that the challenge proof of work page doesn't need to be presented to users that are much more likely to be legitimate.
Please note that Anubis requires the use of modern JavaScript features that plugins like JShelter will disable. Please disable JShelter or other such plugins for this domain.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
is the canonical version.